insulin lispro
insulin lispro: sourced relationships with 1 company · 2 clinical trials tracked · 1 FDA decision.
insulin lispro evidence translation
What we can confirm
1 FDA record · 2 tracked trials
What it means
What to watch
Prepared research question
How could insulin lispro → LLY affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| ELI LILLY & Co (LLY) Reported 2020-06-15 · Current development: unknownSource Carcinoma, Transitional Cell | Approved |
Clinical Trial Registry Records (2)
A Four-Part, Randomized, Double-Blind (Part A) and Open-Label (Part B, Part C, and Part D), Multi-Dose, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus
Primary endpoint: Part A: Number of participants with one or more Adverse Event (s) (AEs), and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration.
A 26- Week, Multicenter, Open-Label, Single-Arm, Phase 4 Study to Assess The Safety of Lyumjev in Adult Patients With Type 2 Diabetes Mellitus in India
Primary endpoint: Percentage of Participants With at Least 1 Documented Hypoglycemic Event With Blood Glucose <54 Milligrams Per Deciliter (mg/dL)
FDA Decisions1 records
Frequently asked questions
Which companies have sourced relationships with insulin lispro?
insulin lispro has dated SEC/FDA relationship records for ELI LILLY & Co.
How many clinical trials involve insulin lispro?
BioSniper tracks 2 clinical trials involving insulin lispro.
What is insulin lispro's latest FDA decision?
The most recent tracked FDA decision for insulin lispro is Approval for 1 INDICATIONS AND USAGE LYUMJEV ® is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. LYUMJEV ® is a rapid-acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. ( 1 ), dated June 15, 2020.